title: Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.
abstract: Oxymorphone (OM), a prescription opioid and metabolite of oxycodone, was included in the recently published proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. To facilitate toxicological interpretation, this study characterized the time course of OM and its metabolite, noroxymorphone (NOM), in hydrolyzed and non-hydrolyzed urine specimens. Twelve healthy subjects were administered a single 10 mg controlled-release OM dose, followed by a periodic collection of pooled urine specimens for 54 h following administration. Analysis for free and total OM and NOM was conducted by liquid chromatography tandem mass spectrometry (LC-MS-MS), at a 50 ng/mL limit of quantitation (LOQ). Following enzymatic hydrolysis, OM and NOM were detected in 89.9% and 13.5% specimens, respectively. Without hydrolysis, OM was detected in 8.1% specimens, and NOM was not detected. The mean ratio of hydrolyzed OM to NOM was 41.6. OM was frequently detected in the first pooled collection 0-2 h post-dose, appearing at a mean of 2.4 h. NOM appeared at a mean of 8.3 h. The period of detection at the 50 ng/mL threshold averaged 50.7 h for OM and 11.0 h for NOM. These data support that OM analysis conducted using a 50 ng/mL threshold should include hydrolysis or optimize sensitivity for conjugated OM.
authors.affiliation: Aegis Sciences Corporation, 515 Great Circle Road, Nashville, TN University of Tennessee Health Science Center, College of Pharmacy, Memphis, TN annedepriest@gmail.com.
authors.forename: Anne Z
authors.initials: AZ
authors.lastname: DePriest
authors.affiliation: Aegis Sciences Corporation, 515 Great Circle Road, Nashville, TN.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Heltsley
authors.affiliation: Aegis Sciences Corporation, 515 Great Circle Road, Nashville, TN Vanderbilt University, Department of Pathology, Microbiology, and Immunology, Nashville, TN.
authors.forename: David L
authors.initials: DL
authors.lastname: Black
authors.affiliation: RTI International, Research Triangle Park, NC.
authors.forename: John M
authors.initials: JM
authors.lastname: Mitchell
authors.affiliation: Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Workplace Programs (DWP), Rockville, MD.
authors.forename: Charles
authors.initials: C
authors.lastname: LoDico
authors.affiliation: Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Workplace Programs (DWP), Rockville, MD.
authors.forename: Ronald
authors.initials: R
authors.lastname: Flegel
authors.affiliation: Johns Hopkins School of Medicine, Baltimore, MD.
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Cone
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000652:urine*; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000652:urine; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D009019:Morphinans / Q000652:urine; D010098:Oxycodone / Q000652:urine; D010111:Oxymorphone / Q000008:administration & dosage / Q000652:urine*; D015813:Substance Abuse Detection / Q000379:methods*; D053719:Tandem Mass Spectrometry; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D009019:Morphinans; C526569:noroxymorphone; D010111:Oxymorphone; D003404:Creatinine; D010098:Oxycodone